This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kovács, J. Articles by Waldhauser, F. Search for Related Content PubMed PubMed Citation Articles by Kovács, J. Articles by Waldhauser, F.

Lessons From 30 Years of Clinical Diagnosis and Treatment of Congenital Adrenal Hyperplasia in Five Middle European Countries¹

Department of Pediatrics (J.K., H.F., F.W.), University of Vienna, A-1090 Vienna, Austria; Department of Pediatrics (F.V., J.L.), 3rd Faculty of Medicine, Charles University, CZ-10081 Prague, Czech Republic; Department of Medical Computer Sciences (G.H.), University of Vienna, A-1000 Vienna, Austria; 2nd Department of Pediatrics (J.S.), Semmelweis University, H-1094 Budapest, Hungary; 2nd Department of Pediatrics (Z.P.), Comenius University, SK-83340 Bratislava, Slovakia; University Children’s Hospital (T.B.), University Medical Center, SLO-61104 Ljubljana, Slovenia; and Department of Pediatrics (J.K.), University of Szeged, H-6720 Szeged, Hungary

Address all correspondence and requests for reprints to: Franz Waldhauser, M.D., Department of Pediatrics, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

Abstract

Despite the fact that congenital adrenal hyperplasia (CAH) is one of the most common inborn endocrine disorders, some patients are not identified, or may even die, in an acute salt-losing crisis. In a retrospective study covering the last 30 yr, we examined the time elapsing before diagnosis of CAH patients, in 5 Middle European countries, and the mortality rate in diagnosed patients and their siblings during childhood; we also attempted to estimate how many patients are not diagnosed clinically each year.

Basic and follow-up clinical data and the family histories of 484 patients with classical forms of CAH diagnosed between 1969 and 1998 were collected and recorded in 5 Middle European countries. The sex-ratio, time elapsing before diagnosis, and mortality among siblings and patients were calculated, and the number of undiagnosed patients was estimated.

We found significantly fewer genetic males (43.0%) than females (57.0%) among 484 classic CAH patients, and the percentage of diagnosed boys did not increase with time; 64.7% of them suffered from the salt-wasting (SW) form, and 35.3% from the simple virilizing (SV) form, of the disease. The diagnosis of CAH was established significantly later in males than in females in both forms [SW: 26 vs. 13 days (median), P < 0.0001; SV: 5.0 vs. 2.8 yr, P = 0.03]. Infant mortality in the general population was significantly lower than in either siblings (1.8% vs. 7.0%; P < 0.0001) or in SW (2.29% vs. 11.3%; P < 0.0001). According to our calculations, by our current praxis of clinical ascertainment, 2–2.5 SW and up to 5 SV stay undiagnosed, out of 40 expected CAH patients per year in the countries investigated. Both clinical detection and treatment of CAH patients, at least in males, were insufficient in the five Middle European countries examined during the last 30 yr. Neonatal mass screening and/or greater awareness of the medical community are discussed as ways of improving the efficacy of CAH management. Our experience may be applicable to other countries with similar health care systems.

This article has been cited by other articles:

				D. I. Shulman, M. R. Palmert, S. F. Kemp, and for the Lawson Wilkins Drug and Therapeutics Commi Adrenal Insufficiency: Still a Cause of Morbidity and Death in Childhood Pediatrics, February 1, 2007; 119(2): e484 - e494. [Abstract] [Full Text] [PDF]

				C. I. Kaye and and the Committee on Genetics Newborn Screening Fact Sheets Pediatrics, September 1, 2006; 118(3): e934 - e963. [Abstract] [Full Text] [PDF]

				A Luczay, D Torok, A Ferenczi, J Majnik, J Solyom, and G. Fekete Potential advantage of N363S glucocorticoid receptor polymorphism in 21-hydroxylase deficiency. Eur. J. Endocrinol., June 1, 2006; 154(6): 859 - 864. [Abstract] [Full Text] [PDF]

				V Dolz;an, J Solyom, G Fekete, J Kovacs, V Rakosnikova, F Votava, J Lebl, Z Pribilincova, S. Baumgartner-Parzer, S Riedl, et al. Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype association in Middle European patients with congenital adrenal hyperplasia Eur. J. Endocrinol., July 1, 2005; 153(1): 99 - 106. [Abstract] [Full Text] [PDF]

				F. Votava, D. Torok, J. Kovacs, D. Moslinger, S. M Baumgartner-Parzer, J. Solyom, Z. Pribilincova, T. Battelino, J. Lebl, H. Frisch, et al. Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia Eur. J. Endocrinol., June 1, 2005; 152(6): 869 - 874. [Abstract] [Full Text] [PDF]

				R. Perry, O. Kecha, J. Paquette, C. Huot, G. Van Vliet, and C. Deal Primary Adrenal Insufficiency in Children: Twenty Years Experience at the Sainte-Justine Hospital, Montreal J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3243 - 3250. [Abstract] [Full Text] [PDF]